Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
Bhatt, Deepak L. , Moliterno, David J. , Cannon, Christopher P. , Tanguay, Jean-François, Granger, Christopher B. , Holmes, David R. , Faxon, David P., Bhatt, Deepak L , Granger, Christopher B , Angiolillo, Dominick J. , Goodman, Shaun G. , Eikelboom, John W. , Price, Matthew J. , Tanguay, Jean‐François , Mauri, Laura , Gibson, C. Michael

Mayo Clinic

Circulation | September 16, 2018 | Volume: 138 | Issue: 5 | Pages: 527-536

10.1161/circulationaha.118.034722 | PMID 30571525 Get It

The optimal antithrombotic treatment regimen for patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation represents a challenge in clinical practice. In 2016, an updated opinion of selected experts from the United States and Canada on the treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention was reported. After the 2016 North American consensus statement on the management of antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention, results of pivotal clinical trials assessing the type of oral anticoagulant agent and the duration of antiplatelet treatment have been published. On the basis of these results, this focused update on the antithrombotic management of patients with atrial fibrillation undergoing percutaneous coronary intervention recommends that a non–vitamin K antagonist oral anticoagulant be preferred over a vitamin K antagonist as the oral anticoagulant of choice. Moreover, a double-therapy regimen (oral anticoagulant plus single antiplatelet therapy with a P2Y 12 inhibitor) by the time of hospital discharge should be considered for most patients, whereas extending the use of aspirin beyond hospital discharge (ie, triple therapy) should be considered only for selected patients at high ischemic/thrombotic and low bleeding risks and for a limited period of time. The present document provides a focused updated on the rationale for the new expert consensus–derived recommendations on the antithrombotic management of patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention.
PS01.134: WHERE TO START? COMPARING INDUCTION CHEMORADIOTHERAPY AND UPFRONT SURGERY IN THE TREATMENT OF CLINICAL T2N0 ESOPHAGEAL CANCER
Agzarian, John , Inra, Matthew L. , Abdelsattar, Zaid M. , Cassivi, Stephen D. , Nichols, Francis, Wigle, Dennis A. , Shen, K. Robert , Allen, Mark S. , Blackmon, Shanda , Nichols, Francis C.

Mayo Clinic

Diseases of the Esophagus | September 16, 2018 | Volume: 31 | Issue: Supplement_1 | Pages: 87-88

10.1093/dote/doy089.ps01.134 Get It

Abstract Background The purpose of this study was to evaluate the survival difference in clinical T2N0 esophageal cancer patients receiving neoadjuvant chemoradiotherapy (CRT) vs. upfront surgery. Methods Between 1/1/1995 to 12/31/2012, a prospectively maintained database was used to identify patients with cT2N0 esophageal adeno- and squamous cell carcinoma. Exclusion criteria included: lack of endoscopic esophageal ultrasonographic (EUS) staging, incomplete resection, and prior treatment with endoscopic mucosal or submucosal resection. Cox-proportional hazard ratios were used to compare the primary outcomes of overall (OS) and disease-free survival (DFS). Secondary outcomes included: rate of postoperative complications, rate of pathologic upstaging/response, and induction/adjuvant treatment completion rate. Pre-hoc subgroup analysis compared pathologically upstaged patients receiving upfront surgery followed by adjuvant chemotherapy to those treated with neoadjuvant CRT. Results A total of 161 cT2N0 esophageal cancer patients were identified based on EUS staging. Upfront surgery was offered to 134 patients (83%), with 27 patients (17%) receiving induction CRT. Univariate analysis did not demonstrate any significant baseline differences between the two groups. In the upfront surgery group, 53 (39.6%), 28 (20.9%) and 53 (39.6%) patients were pathologically down-staged, accurately staged and upstaged respectively. Upstaging was higher in the upfront surgery group (53/134, 39.6% vs. 4/27, 14.8%; P = 0.02), while 11/27 (40.7%) patients receiving neoadjuvant CRT demonstrated complete pathologic response. Of those eligible for adjuvant chemotherapy, only 21/55 (38.2%) received treatment. In the neoadjuvant CRT group, 51.9% completed all planned therapy, compared to 23.6% of patients treated with upfront surgery followed by adjuvant chemotherapy (P = 0.01). Cox proportional hazard ratio did not demonstrate an advantage to induction CRT in terms of OS (HR = 1.64, P = 0.43) or DFS (HR = 1.36, P = 0.69). In general, patients with pathologic upstaging had worse OS (HR = 2.73, P = 0.001) and DFS (HR = 4.18, P = 0.003). Conclusion EUS was only accurate in staging T2N0 patients in 20.9% of cases. While neoadjuvant CRT did not confer a survival advantage, these results likely reflect the low number of patients being referred for induction therapy. Neoadjuvant CRT was however associated with lower rates of pathologic upstaging and higher rates of treatment completion. Further research should evaluate the survival outcomes in pathologically upstaged cT2N0 patients not receiving neoadjuvant therapy. Disclosure All authors have declared no conflicts of interest.
Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy
Berkeley, Robert A., Steele, Lynette P., Mulder, Aat A. , Wollenberg, Diana J.M. van den , Kottke, Timothy, Thompson, Jill , Coffey, Matthew, Hoeben, Rob C. , Vile, Richard G. , Melcher, Alan , Ilett, Elizabeth J. , Kottke, Timothy J, Ilett, Elizabeth J , Melcher, Alan A

Mayo Clinic

Cancer Immunology Research | September 12, 2018 | Volume: 6 | Issue: 10 | Pages: 1161-1173

10.1158/2326-6066.cir-18-0309 | PMID 30209061 Get It

Abstract Immunotherapy is showing promise for otherwise incurable cancers. Oncolytic viruses (OVs), developed as direct cytotoxic agents, mediate their antitumor effects via activation of the immune system. However, OVs also stimulate antiviral immune responses, including the induction of OV-neutralizing antibodies. Current dogma suggests that the presence of preexisting antiviral neutralizing antibodies in patients, or their development during viral therapy, is a barrier to systemic OV delivery, rendering repeat systemic treatments ineffective. However, we have found that human monocytes loaded with preformed reovirus–antibody complexes, in which the reovirus is fully neutralized, deliver functional replicative reovirus to tumor cells, resulting in tumor cell infection and lysis. This delivery mechanism is mediated, at least in part, by antibody receptors (in particular FcγRIII) that mediate uptake and internalization of the reovirus/antibody complexes by the monocytes. This finding has implications for oncolytic virotherapy and for the design of clinical OV treatment strategies. Cancer Immunol Res; 6(10); 1161–73. ©2018 AACR.
Clinical and Radiological Follow-up of Intraneural Perineuriomas
Wilson, Thomas J. , Amrami, Kimberly K. , Howe, B. Matthew, Spinner, Robert J.

Mayo Clinic

Neurosurgery | September 11, 2018 | Volume: 85 | Issue: 6 | Pages: 786-792

10.1093/neuros/nyy476 | PMID 30481319 Get It

ABSTRACT BACKGROUND Management of intraneural perineuriomas remains controversial, largely due to the lack of knowledge regarding the natural history of these lesions. OBJECTIVE To describe the typical radiological growth pattern of intraneural perineuriomas and to determine how the pattern of growth relates to clinical progression. METHODS We performed a retrospective review of the magnetic resonance imaging (MRI) studies and serial clinical examinations of a cohort of patients with biopsy-proven intraneural perineuriomas who had 2 MRI studies at least 2 yr apart. The outcome of interest was radiological growth in length or width of the intraneural perineurioma. Radiological growth was tested for association with clinical progression. RESULTS Twenty patients were included in the study. By width, the lesions were on average larger on repeat imaging ( P = .009). By absolute length, the lesions were on average longer on repeat imaging ( P = .02). By lesion:landmark ratio, there was no difference in length of the lesions between sequential images ( P = .09), with 10 (50%) lesions being shorter and 7 (35%) showing no change. No lesions grew to involve a new nerve or division of a nerve on sequential imaging. None of the variables tested were associated with clinical progression. CONCLUSION We found that intraneural perineuriomas only rarely grow in length, do not grow to involve new nerves or nerve divisions, and growth does not correlate with clinical progression. These findings have significant ramifications for management of these tumors.
Breast Cancer Screening: Women's Attitudes and Beliefs in Light of Updated United States Preventive Services Task Force and American Cancer Society Guidelines
Mehta, Jaya , MacLaughlin, Kathy L. , Millstine, Denise , Wallace, Mark R. , Shah, Amit , Fields, Heather , Ruddy, Barbara E., Bryan, Michael , Patel, Bhavika , Temkit, M’hamed , Buras, Matthew , Golafshar, Michael A. , Kling, Juliana M. , Mehta, Jaya M, Millstine, Denise M, Shah, Amit A, Fields, Heather E, Bryan, Michael J, Patel, Bhavika K , Buras, Matthew R , Golafshar, Michael , Kling, Juliana M , Shah, Amit A , Faubion, Stephanie S.

Mayo Clinic

Journal of Women's Health | September 11, 2018 | Volume: 28 | Issue: 3 | Pages: 302-313

10.1089/jwh.2017.6885 | PMID 30204537 Get It

Superior Canal Dehiscence Involving the Superior Petrosal Sinus: A Novel Classification Scheme
Sweeney, Alex D. , O’Connell, Brendan P., Patel, Neil S. , Tombers, Nicole M. , Wanna, George B. , Lane, John I. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | September 10, 2018 | Volume: 39 | Issue: 9 | Pages: e849-e855

10.1097/mao.0000000000001965 | PMID 30199501 Get It

Objectives: To highlight superior semicircular canal dehiscence (SSCD) involving the superior petrosal sinus (SPS), and to propose a novel classification system for SPS associated SSCD with potential surgical implications. Study Design: Multicenter retrospective review. Setting: Three tertiary referral centers. Patients: All patients diagnosed with SPS associated SSCD (1/2000 to 8/2016). Radiographic findings and clinical symptoms were analyzed. Intervention: Surgical repair or observation. Main Outcome Measure: Radiographic findings and clinical symptoms were analyzed. Results: Thirty-three dehiscences (30 patients) involving the SPS were identified. The average age at the time of presentation was 52.5 years (median, 56.9; range, 4.9–75.3 yr), and 53.3% of patients were men. Three patients had bilateral SPS associated SSCD. The most common associated symptoms at presentation were episodic vertigo (63.6%), subjective hearing loss (60.6%), and aural fullness (57.6%). Four distinct types of dehiscence were identified: class Ia. SSCD involving a single dehiscence into an otherwise normal appearing SPS; class Ib. SSCD involving a single dehiscence into an apparent venous anomaly of the SPS; class IIa. SSCD involving two distinct dehiscences into the middle cranial fossa and the SPS; class IIb. SSCD involving a single confluent dehiscence into the middle cranial fossa and the SPS. Conclusions: SSCD involving the SPS represents a small but distinct subset of SSCD cases. This scenario can create a unique set of symptoms and surgical challenges when intervention is sought. Clinical findings and considerations for surgical intervention are provided to facilitate effective diagnosis and management.
Blood clotting and traumatic injury with shock mediates complement-dependent neutrophil priming for extracellular ROS, ROS-dependent organ injury and coagulopathy
Barrett, Christopher D. , Hsu, Albert, Ellson, Chris D., Miyazawa, Byron , Kong, Y-W, Greenwood, J D, Sperry, Jason L., Park, M S, Cohen, Mitchell J. , Zuckerbraun, Brian S. , Kong, Yi Wen , Kong, Y-W, Dhara, Sanjeev S. , Neal, Matthew D , Yaffe, Michael B.

Mayo Clinic

Clinical and Experimental Immunology | September 9, 2018 | Volume: 194 | Issue: 1 | Pages: 103-117

10.1111/cei.13166 | PMID 30260475 Get It

SummaryPolymorphonuclear (PMN) leucocytes participate in acute inflammatory pathologies such as acute respiratory distress syndrome (ARDS) following traumatic injury and shock, which also activates the coagulation system systemically. Trauma can prime the PMN nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex for an enhanced respiratory burst, but the relative role of various priming agents in this process remains incompletely understood. We therefore set out to identify mediators of PMN priming during coagulation and trauma-shock and determine whether PMN reactive oxygen species (ROS) generated in this manner could influence organ injury and coagulation. Initial experiments demonstrated that PMN are primed for predominantly extracellular ROS production by products of coagulation, which was abrogated by CD88/C5a receptor(C5aR) inhibition. The importance of this was highlighted further by demonstrating that known PMN priming agents result in fractionally different amounts of extracellular versus intracellular ROS release depending on the agent used. Plasma from trauma patients in haemodynamic shock (n = 10) also primed PMN for extracellular ROS in a C5a-dependent manner, which correlated with both complement alternative pathway activation and thrombin generation. Furthermore, PMN primed by preincubation with products of blood coagulation directly caused loss of endothelial barrier function in vitro that was abrogated by C5aR blockade or NADPH oxidase inhibition. Finally, we show in a murine model of trauma-shock that p47phox knock-out (KO) mice with PMN incapable of generating ROS were protected from inflammatory end-organ injury and activated protein C-mediated coagulopathy. In summary, we demonstrate that trauma-shock and coagulation primes PMN for predominantly extracellular ROS production in a C5a-dependent manner that contributes to endothelial barrier loss and organ injury, and potentially enhances traumatic coagulopathy.
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy
Buzdar, Aman U. , Leitch, A. Marilyn , Unzeitig, Gary, Royce, Melanie , Suman, Vera J. , Meric‐Bernstam, Funda , Ellis, Matthew J. , Boughey, Judy C. , Hunt, Kelly K.

Mayo Clinic

JAMA Oncology | September 7, 2018 | Volume: 5 | Issue: 1 | Pages: 45

10.1001/jamaoncol.2018.3691 | PMID 30193295 Get It

Cochlear Implantation: An Overview
Deep, Nicholas L. , Dowling, Eric M. , Jethanamest, Daniel , Carlson, Matthew L. , Dowling, Eric

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | September 6, 2018 | Volume: 80 | Issue: 02 | Pages: 169-177

10.1055/s-0038-1669411 | PMID 30931225 Get It

AbstractA cochlear implant (CI) is a surgically implanted device for the treatment of severe to profound sensorineural hearing loss in children and adults. It works by transducing acoustic energy into an electrical signal, which is used to stimulate surviving spiral ganglion cells of the auditory nerve. The past 2 decades have witnessed an exponential rise in the number of CI surgeries performed. Continual developments in programming strategies, device design, and minimally traumatic surgical technique have demonstrated the safety and efficacy of CI surgery. As a result, candidacy guidelines have expanded to include both pre and postlingually deaf children as young as 1 year of age, and those with greater degrees of residual hearing. A growing proportion of patients are undergoing CI for off-label or nontraditional indications including single-sided deafness, retrocochlear hearing loss, asymmetrical sensorineural hearing loss (SNHL) in adults and children with at least 1 ear that is better than performance cut-off for age, and children less than 12 months of age. Herein, we review CI design, clinical evaluation, indications, operative technique, and outcomes. We also discuss the expanding indications for CI surgery as it relates to lateral skull base pathology, comparing CI to auditory brainstem implants, and address the concerns with obtaining magnetic resonance imaging (MRI) in CI recipients.